Halozyme Therapeutics (HALO) Q1 2025 Earnings
Halozyme Therapeutics reported Q1 2025 revenue of $264.9M (+35.2% YoY), missed analyst consensus of $281.0M by $16.1M. Diluted EPS came in at $1.11 (+40.5% YoY), beat the $0.95 consensus by $0.16.
Financial Snapshot
Trailing eight quarters through Q1 2025
Q1 2025 Earnings FAQ
Common questions about Halozyme Therapeutics's Q1 2025 earnings report.
Halozyme Therapeutics (HALO) reported Q1 2025 earnings on May 6, 2025 after market close.
Halozyme Therapeutics reported revenue of $264.9M and diluted EPS of $1.11 for Q1 2025.
Revenue missed the consensus estimate of $281.0M by $16.1M. EPS beat the consensus estimate of $0.95 by $0.16.
Compared to the same quarter a year prior, revenue grew 35.2% from $195.9M a year earlier and diluted EPS grew 40.5% from $0.79.
You can read the 10-Q periodic report (0001159036-25-000026) directly on SEC EDGAR. The filing index links above go to sec.gov.